Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The software company co-founder allegedly raised more than $30 million by falsely claiming the company had millions of ...

MStudioImages/E+ via Getty Images The U.S. Securities and Exchange Commission's wide-sweeping investigation into ...

The SEC charges DraftKings with selectively disclosing nonpublic information to investors who followed the company CEO’s social accounts. DraftKings agrees to pay a $200,000 civil penalty to ...

In its correction, the firm also paid out $220,000 to 846 retail customers, accounting for upfront sales charges plus interest. The SEC's examination priorities for 2024 indicated Regulation Best ...

Merrill Lynch, Pierce, Fenner & Smith Inc. and Harvest Volatility Management LLC have agreed to pay a combined $9.3 million ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...

Former SKAEL CEO Baba Nadimpalli is charged by the SEC with a $30 million fraud, accused of inflating revenue and fabricating ...

A former Cetera Financial advisor cherry-picked daily trades for his own benefit, netting about $5.3 million in “illicit” first-day profits, according to new charges from the SEC. The ...